Close menu




February 4th, 2020 | 05:50 CET

Aurora Cannabis, EXMceuticals, Tilray - Cannabis development in Portugal

  • Cannabis
Photo credits: pixabay.com

From the street to the clinic. Cannabis had the image of an illegal street drug in most rich countries since the prohibition in the USA in the 1930s. Although cannabis has been used as a medicinal plant for more than 1,000 years, the past decades have been marked by other pharmaceutical products. The market and attitudes towards cannabis are now changing. Doctors, patients, companies and investors see opportunities to profit from this development.

time to read: 1 minutes | Author: Mario Hose
ISIN: CA30207T1049 , CA05156X1087 , US88688T1007

Table of contents:


    Education is the key to success

    Education and research are often the beginning of a success story. In order for development to progress, knowledge and education are an elementary basis for medical change with cannabis. Doctors, patients and companies must work together to test and evaluate the effects of cannabis in medicine.

    With increasing experience and information in databases the acceptance of cannabis in medicine will increase. Thus the use of medical cannabis preparations can be suggested by physicians or simply demanded by patients.

    Improvement of the quality of life

    The use of and experiences with cannabis products are characterized by objective and subjective characteristics. For example, a cannabis product may cause a patient to sleep much better but not to feel any improvement in pain relief. The bottom line, however, is that the quality of life has subjectively increased due to improved sleep.

    Such developments in practice ensure that cannabis products are accepted in medicine. In this context, however, it is important that patients have easy access to medical cannabis products and also that doctors know what they are prescribing for which therapies.

    Opportunities for investors

    Also the companies invest in the development of the cannabis market and here especially experience counts. Aurora Cannabis, EXMceuticals and also Tilray have different approaches and strategies to conquer the market for cannabis products.

    For investors there is the opportunity to participate in the listed companies to be part of it. Even if the share prices of most cannabis companies have been declining in recent months, the trend in use and therapy will continue. It will probably only be a matter of time when this development will be reflected in the stock market prices again.

    Portugal as cannabis centre

    EXMceuticals, a manufacturer of high quality cannabis extracts for use in the pharmaceutical and nutraceutical industry as well as in therapy and cosmetics, announced yesterday that Prf. Dr. Eurico Castro Alves has been appointed to the company's advisory board.

    Commenting on the appointment, Jonathan Summers, CEO of the company, said: "He and EXM share a common goal to establish Portugal as a centre for medical Cannabis healthcare and science. The next step is to have in operation, and licensed, a high-quality ingredients factory that will produce to medical standards and have many industrial applications.”


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Nico Popp on February 2nd, 2023 | 18:04 CET

    Bulging pipeline at BioNTech, Cardiol Therapeutics - what is the problem at Aurora Cannabis?

    • Biotechnology
    • Cannabis
    • Cancer

    He who heals is right. It is not quite that simple with active ingredients that are about to be approved. Drugs and vaccines must undergo extensive studies and, last but not least, have to prevail against the existing competition. We look at the pipelines of three hot stocks and venture a forecast: Where is the greatest potential for investors?

    Read

    Commented by Fabian Lorenz on December 1st, 2022 | 11:55 CET

    Comeback stocks: Nel, Aurora Cannabis, Barrick Gold, Tocvan Ventures

    • Mining
    • Gold
    • Hydrogen
    • Cannabis

    Gold, cannabis and hydrogen could be among the top trends of the coming year - also on the stock market. Due to full order books, Nel could be poised for a comeback in 2023. At least sales are already secured until mid-2024. Now, all that is left is to cut the loss to reach analysts' price targets. Aurora Cannabis has largely completed its turnaround and is also hoping for legalization in Europe and the US. Driven by a strong gold price, mining stocks have already jumped. Now exploration companies should follow. Tocvan Ventures is one of them. And with the gold explorer, investors can look forward to a regular news flow in the coming year. Are the three candidates comeback stocks in 2023?

    Read

    Commented by Stefan Feulner on November 28th, 2022 | 10:41 CET

    SynBiotic SE, Cardiol Therapeutics, Canopy Growth - Like hitting the jackpot

    • Cannabis
    • Investments

    The final draft of the German government's key issues paper on the legalization of cannabis in Germany is ready, and final approval is likely to be a mere formality. For the companies concerned, this is equivalent to winning the lottery. The global cannabis market is expected to grow by 13.9% annually to USD 64.91 billion between 2022 and 2027. However, these profit increases have yet to reach the stock market. Some companies, for example, are trading below cash, while others lost more than 90% of their value in the correction that has been underway since 2019.

    Read